Merck KGaA Ends Theratope Cancer Vaccine Co-Development; Biomira Seeks New Partner

Merck decided against pursuing development of the oncologic following a disappointing Phase III trial because additional trials would likely be needed to support a regulatory submission. Biomira says it does not have enough cash to support an additional Phase III program on its own.